• LinkedIn
  • Facebook
  • Instagram
  • Twitter
  • Five_100_px
 
Anuncia
  • (978) 942-5600
  • [email protected]
  • Home
  • ABOUT
    • The Anuncia Story
    • Meet the Team
  • RESOURCES
    • News & Blogs
    • Professional Associations
  • For Patients
    • What is Hydrocephalus?
    • Our ReFlow™ Technology
    • Patient Stories
    • Frequently Asked Questions
  • For Clinicians
    • Product Information
  • Investor Relations
  • Careers
  • Contact
  • Menu Menu

Anuncia Inc. Receives FDA “Breakthrough Device Designation” for ReFlow™ System Mini

March 2, 2021

LOWELL, Mass., March 2, 2021 /PRNewswire/ — Anuncia Inc., an emerging leader in Cerebral Spinal Fluid (CSF) management, received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its ReFlow™ System Mini intended for the treatment of CSF disorders requiring shunting such as hydrocephalus, a debilitating and life-threatening condition affecting more than 1 million U.S. patients. Elsa Abruzzo, President of Anuncia Inc., stated, “Our team is very pleased to achieve this significant milestone making the ReFlow™ System Mini eligible for prioritized FDA regulatory review and Centers for Medicare and Medicaid (CMS) Medicare Coverage of Innovation Technology (MCIT) reimbursement review.”

As many as half of all intracranial shunts fail in the first two years, mainly due to blockages that impair CSF flow requiring emergency revision surgery, each costing upwards of $40,000. The breakthrough indication would allow in-clinic or at-home prophylactic flushing noninvasively by trained patients, caregivers, and clinicians to potentially prevent blockages. “The ReFlow™ System Mini is optimized to serve a broad hydrocephalus population—infants with non-communicating hydrocephalus, young women with pseudotumor cerebri, and older patients with communicating, idiopathic normal pressure hydrocephalus (iNPH). iNPH is known as the treatable dementia and is often misdiagnosed as Alzheimer’s or Parkinson’s,” commented Mark Luciano, MD, Ph.D., Director of the Cerebral Fluid Center and Professor of Neurosurgery at John Hopkins University in Baltimore.

In a preliminary study of patients at risk for shunt occlusion by two US pediatric centers of excellence, all intracranial shunts remained patent beyond one year using prophylactic flushing with the current ReFlow System. More than half of the patients are nearing their two-year, occlusion-free shunt anniversary. Ramin Eskandari, MD MS, Chief of Pediatric Neurosurgery at the Medical University of South Carolina, remarked, “The ReFlow™ System Mini is unique in that it could be used with any newly implanted or revised shunt system in any size patient. Coupled with at-home, noninvasive prophylactic flushing, the ReFlow™ System Mini may decrease emergent hospitalizations, reduce patient and healthcare system costs, and improve the everyday quality of life and overall clinical outcomes for these vulnerable patients living with hydrocephalus.”

About ReFlow System and ReFlow™ System Mini
The current ReFlow System is FDA cleared and CE Marked for use by a qualified clinician to facilitate a safe, noninvasive retrograde fluid flush when ventriculoperitoneal shunt flow is restricted or blocked. The ReFlow™ System Mini is under development and not available for sale. The ReFlow System is a prescription device sold by or on the order of a physician.

About Anuncia Inc.
Anuncia Inc., based in Lowell, Massachusetts, is a privately held therapeutic medical device company and an emerging leader in treating conditions associated with Cerebral Spinal Fluid disorders through innovative devices. For more information, please visit www.anunciainc.com

https://anunciamedical.com/wp-content/uploads/2021/12/fda-approved-medical-device-reflow-anuncia-min.jpg 400 600 admin https://anunciamedical.com/wp-content/uploads/2023/12/LowResPNG__Anuncia-Stacked_COLOR_.png admin2021-03-02 02:57:152023-07-26 20:57:50Anuncia Inc. Receives FDA “Breakthrough Device Designation” for ReFlow™ System Mini

Pages

  • Careers
  • Contact
  • Cookie Policy
  • FAQs
  • For Clinicians
  • Home
  • Investor Relations
  • News & Blogs
  • Our Technology
  • Patient Stories
  • Privacy Policy
  • Professional Associations
  • Publications
  • Thank You!
  • The Anuncia Story
  • What is Hydrocephalus?

Categories

  • Anuncia News
  • Educational Information
  • Press Releases
  • Uncategorized

Archive

  • March 2025
  • June 2024
  • December 2023
  • August 2023
  • July 2023
  • May 2023
  • October 2022
  • March 2022
  • February 2022
  • July 2021
  • June 2021
  • May 2021
  • March 2021
  • May 2019
  • December 2018
  • May 2018
  • February 2018

Contact your physician to discuss if the ReFlow™ System Mini may be right for you.

Additional information about the ReFlow™ System Mini is available by contacting Anuncia.

(978) 942-5600 | [email protected]

Our Address

6908 E Thomas Road
Suite 302
Scottsdale, AZ 85251

Directions

Disclaimer

The ReFlow™ System Mini and ReFlow Mini Flusher are FDA cleared for use in the treatment of patients with hydrocephalus or conditions where draining or shunting of cerebrospinal fluid (CSF) is medically indicated. The ReFlow™ System Mini and ReFlow™ Mini Flusher are not for everyone; please consult your doctor. The ReFlow™ System Mini and ReFlow™ Mini Flusher are only available in the United States. The ReFlow™ System Mini and ReFlow™ Mini Flusher are prescription devices sold by or on the order of a physician.

Caution: FDA (USA) law restricts this device to sale by or on the order of a physician. Refer to product package insert for instructions, warnings, precautions and complications.

Medical Advice Disclaimer

Information on this site is for informational purposes only and should not be used as a substitute for talking with your doctor. No representation is made that the information provided is current, complete, or accurate. Always consult with your doctor about your medical questions, health, diagnosis, and treatment information.

Trademark Legal Notice

All logos, and brands are property of their respective owners in the United States and/or other countries. All company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.

Anuncia Inc. is not affiliated with or an official partner of MD&DI, Fast Company, and The FDA.

© 2024 Anuncia Inc. All Rights Reserved. Website by Honeywick   |   Privacy Policy   |   Cookie Policy
Scroll to top

Contact Us